Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients

Blood Purification

Volumn 37, Issue 2, 2014, Pages 106-112

  Okazaki, Masayuki ^a   Komatsu, Mizuki ^a   Kawaguchi, Hiroshi ^a   Tsuchiya, Ken ^b   Nitta, Kosaku ^b  

^a Fukushima   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anemia; End stage renal disease; Epoetin; Erythropoietin; Hyporesponsiveness; Mortality

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; FERRITIN; HEPCIDIN;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG RESISTANCE; ERYTHROPOIETIN RESISTANCE INDEX; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; AGED; BLOOD; COMPLICATION; FOLLOW UP; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; BLOOD VESSEL PARAMETERS; HEMODIALYSIS; KAPLAN MEIER METHOD; RISK FACTOR;

AGED; ANEMIA; CAUSE OF DEATH; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HEPCIDINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84895697487     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000358215     Document Type: Article

References (26)

1. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78. (Pubitemid 17052741)
2. Macdougall IC, Cooper A: The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17(suppl 1):48-52. (Pubitemid 34157120)
3. Zhang Y, Thamer M, Stefanik K, et al: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876. (Pubitemid 39445919)
4. Kilpatrick R, Critchlow C, Fishbane S, et al: Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
5. Locatelli F, Pisoni R, Combe C, et al: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132. (Pubitemid 38072623)
6. Robinson BM, Joffe MM, Berns JS, et al: Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68: 2323-2330. (Pubitemid 43117811)
7. Johnson DW, Pollock CA, Macdougall IC: Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007; 12: 321-330.
8. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(suppl 3):S16-S145.
9. Locatelli F, Aljama P, Barany P; European Best Practice Guidelines Working Group: Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(suppl 2):ii1-ii47.
10. Chung S, Song HC, Shin SJ, et al: Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. Hemodial Int 2012; 16: 181-187.
11. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213.
12. Murao N, Ishigai M, Yasuno H, et al: Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/ selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007; 21: 4033-4038.
13. Tsubakihara Y, Nishi S, Akiba T, et al: 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240-275.
14. Scott DS: Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendation from clinical studies. Pharmacotherapy 2002; 22: 160S-165S.
15. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-881. (Pubitemid 37322905)
16. Lopez-Gomez JM, Portoles JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation mortality. Kidney Int Suppl 2008; 111:S75-S81.
17. Streja E, Kovesdy CP, Molnar MZ, et al. Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis 2011; 57: 883-893.
18. Movilli E, Cancarini GC, Zani R, et al: Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 111-114. (Pubitemid 32051482)
19. Mallick S, Rafiroiu A, Kanthety R, et al: Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif 2012; 33: 238-244.
20. Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M: Renal anemia of inflammation: the name is self-explanatory. Blood Purif 2011; 32: 220-225.
21. Coyne DW: Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011; 80: 240-244.
22. Kilpatrick RD, Critchlow CW, Fishbane S, et al: Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
23. Panichi V, Rosati A, Bigazzi R, et al: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648.
24. Fukuma S, Yamaguchi T, Hashimoto S, et al: Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 2012; 59: 108-116.
25. Nishio A, Chhatkuli BP, Ma JZ, Kalantari K: Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif 2013; 36: 29-36.
26. Nakai S, Iseki K, Itami N, et al: An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial 2012; 16: 483-521.